Capecitabine
An oral chemotherapy drug that is converted in the body, particularly in tumor tissue, to the active compound 5-fluorouracil, which inhibits cancer cell DNA synthesis. It is used to treat colorectal cancer, breast cancer, and gastric cancer. This prodrug approach allows oral administration while concentrating the active agent in tumors.
Molecular Weight
359.3500 g/mol
LogP
0.60
TPSA
121.00 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
2D Structure
Cite this structure
Embed this structure
SMILES
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F
InChI
InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
Molecular Formula
C15H22FN3O6
HBD / HBA
3 / 7
Rotatable Bonds
7
Heavy Atoms
25
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
An oral chemotherapy drug that is converted in the body, particularly in tumor tissue, to the active compound 5-fluorouracil, which inhibits cancer cell DNA synthesis. It is used to treat colorectal cancer, breast cancer, and gastric cancer. This prodrug approach allows oral administration while concentrating the active agent in tumors.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Capecitabine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1773. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 60953. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="capecitabine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/capecitabine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/capecitabine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/capecitabine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="capecitabine"></drugfyi-drug>